The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are: 1. The effect of metformin on olanzapine-induced metabolic disturbance 2. The effect of metformin on olanzapine-induced hyperprolactinemia Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Glucose level
Timeframe: 8 weeks
prolactin level
Timeframe: 8 weeks
Insulin level
Timeframe: 8 weeks
low-density lipoprotein cholesterol (LDL-C) level
Timeframe: 8 weeks
high-density lipoprotein cholesterol (HDL-C) level
Timeframe: 8 weeks
cholesterol level
Timeframe: 8 weeks
triglycerides level
Timeframe: 8 weeks
leptin level
Timeframe: 8 weeks